Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
AbbVie Says Health Canada Issues Notice of Compliance for EPKINLY in Follicular Lymphoma

AbbVie Says Health Canada Issues Notice of Compliance for EPKINLY in Follicular Lymphoma

MT newswireMT newswire2026/09/24 11:56
07:56 AM EDT, 09/24/2026 (MT Newswires) -- AbbVie (ABBV) said Thursday that Health Canada issued a Notice of Compliance for EPKINLY, or epcoritamab, for a new indication to treat adults with follicular lymphoma, a subtype of non-Hodgkin lymphoma. EPKINLY, in combination with lenalidomide and rituximab, is indicated to treat patients with relapsed or refractory Grade 1, 2, or 3a follicular lymphoma who have received at least one prior line of systemic therapy, the company said. AbbVie said the approval was supported by results from its phase 3 EPCORE FL-1 study, which showed that EPKINLY, in combination with lenalidomide and rituximab, reduced the risk of disease progression or death by 79% compared with lenalidomide and rituximab alone. AbbVie said it is developing EPKINLY with Genmab as part of an oncology collaboration.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

SoftBank Group’s credit risk rises to a four-year high, as AI bets and acquisition rumors heighten leverage concerns

Due to increased market concerns over AI-related financing and potential large-scale acquisitions, SoftBank Group's credit risk indicator—the credit default swap (CDS)—has risen to its highest level in nearly four years.

智通财经•2026/10/20 04:06
SoftBank Group’s credit risk rises to a four-year high, as AI bets and acquisition rumors heighten leverage concerns

Microsoft (MSFT.US) faces a "higher bar" after its rebound! Morgan Stanley remains bullish: Azure growth and Copilot commercialization are key drivers, target price set at $600

Morgan Stanley stated that Microsoft's stock price has recently rebounded, so the tech giant will face a "higher hurdle" if it wants to maintain its upward momentum.

智通财经•2026/10/20 03:52
Microsoft (MSFT.US) faces a "higher bar" after its rebound! Morgan Stanley remains bullish: Azure growth and Copilot commercialization are key drivers, target price set at $600

Report: OpenAI plans to accelerate fundraising before Anthropic goes public

OpenAI is racing against time—in order to secure funding ahead of rival Anthropic’s IPO, the company has significantly compressed its fundraising timeline, aiming to complete approximately $30 billion in private financing, which could push its valuation past $1.4 trillion upon completion. Major investors such as SoftBank and MGX are already engaged in discussions. Both AI giants are targeting trillion-dollar valuations, and their largely overlapping investor bases are being forced to make simultaneous bets on both ventures within just a few days.

华尔街见闻•2026/10/20 03:46
Report: OpenAI plans to accelerate fundraising before Anthropic goes public